Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[IDAOH-95 Study - Identifying Organisational Improvement Areas to Enhance Resident Care in Nursing Homes in Val-d'Oise - A Practice-Based Survey].

Geriatrie et psychologie neuropsychiatrie du vieillissement·2026
Same author

Care-associated adverse events related to the use of laser in urological interventions: the French experience.

Frontiers in urology·2025
Same author

Characteristics and outcomes of ICU patients with sepsis transmitted by cats and dogs: the PETSEPSIS multicentre retrospective observational cohort study.

Critical care (London, England)·2025
Same author

Corrigendum to "Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics" [Regul. Toxicol. Pharmacol., (161) (2025) 105855].

Regulatory toxicology and pharmacology : RTP·2025
Same author

Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics.

Regulatory toxicology and pharmacology : RTP·2025
Same author

Systems analysis of clinical incidents: development of a new edition of the London Protocol.

BMJ quality & safety·2025

Related Experiment Video

Updated: Jul 17, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Seletracetam (UCB 44212).

Barbara Bennett1, Alain Matagne, Philippe Michel

  • 1CNS Clinical Development, UCB Atlanta, Smyrna, Georgia 30080, USA. Barbara.bennett@ucb-group.com

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 3, 2007
PubMed
Summary

Seletracetam, a novel antiepileptic drug, shows potent seizure suppression and high central nervous system (CNS) tolerability in preclinical models. Initial human studies indicate favorable pharmacokinetics and good tolerability, suggesting it is a promising new epilepsy treatment.

More Related Videos

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Experiment Videos

Last Updated: Jul 17, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epileptology

Background:

  • Current epilepsy pharmacotherapies present limitations for patients with refractory epilepsy or tolerability issues.
  • Seletracetam, a pyrrolidone derivative, is structurally related to levetiracetam and targets the synaptic vesicle 2A (SV2A) protein.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of seletracetam as a potential new antiepileptic drug.
  • To assess the pharmacokinetic profile and potential for drug-drug interactions of seletracetam.

Main Methods:

  • Preclinical evaluation in animal models of acquired and genetic epilepsy.
  • In vitro assessment of drug metabolizing enzyme inhibition/induction and plasma protein binding.
  • Phase I clinical studies in healthy volunteers to determine pharmacokinetics and safety.

Main Results:

  • Seletracetam demonstrated potent seizure suppression and high central nervous system (CNS) tolerability in animal models.
  • Pharmacokinetic studies showed rapid absorption, linear kinetics, and high oral bioavailability (>90%) with an 8-hour half-life in humans.
  • Seletracetam exhibited low potential for drug-drug interactions and mild to moderate, transient adverse events in healthy volunteers.

Conclusions:

  • Seletracetam exhibits a potent, broad-spectrum of seizure protection and favorable CNS tolerability in preclinical studies.
  • Initial clinical data suggest straightforward pharmacokinetics and good tolerability, positioning seletracetam as a promising antiepileptic drug candidate.